Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.

PloS one | 2010

The incidence of esophageal adenocarcinoma (EAC) has risen rapidly in the U.S. and western world. The aim of the study was to begin the investigation of this rapid rise by developing, calibrating, and validating a mathematical disease simulation model of EAC using available epidemiologic data.

Pubmed ID: 20208996 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: K25 CA133141
  • Agency: NCI NIH HHS, United States
    Id: CA107060
  • Agency: NCI NIH HHS, United States
    Id: K07 CA143044
  • Agency: NCI NIH HHS, United States
    Id: CA133141
  • Agency: NCI NIH HHS, United States
    Id: K07 CA107060-05
  • Agency: NCI NIH HHS, United States
    Id: K07 CA107060
  • Agency: NCI NIH HHS, United States
    Id: K07 CA107060-04

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Surveillance Epidemiology and End Results (tool)

RRID:SCR_006902

SEER collects cancer incidence data from population-based cancer registries covering approximately 47.9 percent of the U.S. population. The SEER registries collect data on patient demographics, primary tumor site, tumor morphology, stage at diagnosis, and first course of treatment, and they follow up with patients for vital status.There are two data products available: SEER Research and SEER Research Plus. This was motivated because of concerns about the increasing risk of re-identifiability of individuals. The Research Plus databases require more rigorous process for access that includes user authentication through Institutional Account or multiple-step request process for Non-Institutional users.

View all literature mentions